Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Two investors are alleging Illumina committed fraud through artificial inflation of stock price in connection with its Q3 2016 earnings.

The sequencing giant is migrating its BaseSpace analytics products to AWS in hopes of simplifying user adoption and rapidly expanding its library of curated content.

The Shenzhen-based company offers personal genomics services in China that are similar to those provided by 23andMe, Ancestry, and Helix in the US.

By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.

Solana, founded in 2017 by former Illumina employees, has launched hundreds of products, including DNA sequencing solutions.

NYSDOH's move away from susceptibility testing for isolates that are known to be pan-susceptible will be coordinated with similar international efforts.

Illumina can now sell the instrument in China for IVD purposes. The firm said that the system is its first CNDA-cleared NGS platform in China.

Funds raised through the offering will be used to buy back shares of common stock from shareholders in privately negotiated transactions.

Initial purchasers will also have a 30-day option to purchase up to an addition $100 million of the notes for a potential offering size of $750 million.

The lawsuit makes broad accusations that companies stole trade secrets related to universal array technology.

Pages

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.